Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta‐analysis

左旋西孟旦 医学 内科学 心脏病学 射血分数 心力衰竭 脑利钠肽 利钠肽 冲程容积 变向性 心室重构 置信区间
作者
Xia Wang,Xiaoxian X. Zhao,X Wang,Lu‐Ying Cao,Bin Lü,Zhi‐Hao Wang,Wei Zhang,Yun Ti,Ming Zhong
出处
期刊:Esc Heart Failure [Wiley]
被引量:2
标识
DOI:10.1002/ehf2.14714
摘要

Abstract Heart failure is the final stage of several cardiovascular diseases, and the key to effectively treating heart failure is to reverse or delay ventricular remodelling. Levosimendan is a novel inotropic and vasodilator agent used in heart failure, whereas the impact of levosimendan on ventricular remodelling is still unclear. This study aims to investigate the impact of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction. Electronic databases were searched to identify eligible studies. A total of 66 randomized controlled trials involving 7968 patients were included. Meta‐analysis results showed that levosimendan increased left ventricular ejection fraction [mean difference (MD) = 3.62, 95% confidence interval (CI) (2.88, 4.35), P < 0.00001] and stroke volume [MD = 6.59, 95% CI (3.22, 9.96), P = 0.0001] and significantly reduced left ventricular end‐systolic volume [standard mean difference (SMD) = −0.52, 95% CI (−0.67, −0.37), P < 0.00001], left ventricular end‐diastolic volume index [SMD = −1.24, 95% CI (−1.61, −0.86), P < 0.00001], and left ventricular end‐systolic volume index [SMD = −1.06, 95% CI (−1.43, −0.70), P < 0.00001]. In terms of biomarkers, levosimendan significantly reduced the level of brain natriuretic peptide [SMD = −1.08, 95% CI (−1.60, −0.56), P < 0.0001], N‐terminal pro‐brain natriuretic peptide [SMD = −0.99, 95% CI (−1.41, −0.56), P < 0.00001], and interleukin‐6 [SMD = −0.61, 95% CI (−0.86, −0.35), P < 0.00001]. Meanwhile, levosimendan may increase the incidence of hypotension [risk ratio (RR) = 1.24, 95% CI (1.12, 1.39), P < 0.0001], hypokalaemia [RR = 1.57, 95% CI (1.08, 2.28), P = 0.02], headache [RR = 1.89, 95% CI (1.50, 2.39), P < 0.00001], atrial fibrillation [RR = 1.31, 95% CI (1.12, 1.52), P = 0.0005], and premature ventricular complexes [RR = 1.86, 95% CI (1.27, 2.72), P = 0.001]. In addition, levosimendan reduced all‐cause mortality [RR = 0.83, 95% CI (0.74, 0.94), P = 0.002]. In conclusion, our study found that levosimendan might reverse ventricular remodelling when applied in patients with left ventricular systolic dysfunction, especially in patients undergoing cardiac surgery, decompensated heart failure, and septic shock.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wldsd发布了新的文献求助30
1秒前
充电宝应助王羊补牢采纳,获得10
4秒前
科研通AI2S应助酷酷飞烟采纳,获得10
4秒前
meng发布了新的文献求助30
5秒前
5秒前
完美小蘑菇完成签到,获得积分10
5秒前
兰是一个信仰完成签到,获得积分10
5秒前
潇湘雪月发布了新的文献求助10
8秒前
YJ888发布了新的文献求助10
8秒前
azusa完成签到,获得积分10
12秒前
昔年若许完成签到,获得积分10
19秒前
22秒前
23秒前
25秒前
高手发布了新的文献求助10
25秒前
善学以致用应助1WSQARFGRDSX采纳,获得10
26秒前
ZZZ完成签到,获得积分10
27秒前
ZZZ发布了新的文献求助10
29秒前
一一完成签到 ,获得积分10
29秒前
hp发布了新的文献求助10
31秒前
32秒前
姚世娇完成签到 ,获得积分10
34秒前
FashionBoy应助高手采纳,获得10
35秒前
meng完成签到,获得积分10
36秒前
chennn完成签到,获得积分10
36秒前
38秒前
39秒前
晗月完成签到,获得积分10
39秒前
情怀应助如意枫叶采纳,获得10
40秒前
量子星尘发布了新的文献求助10
42秒前
Akim应助SS采纳,获得10
43秒前
张雷应助清新的夜蕾采纳,获得20
43秒前
chennn发布了新的文献求助10
43秒前
罗一完成签到,获得积分10
45秒前
47秒前
丘比特应助wu采纳,获得10
50秒前
俏皮芷蕊发布了新的文献求助30
50秒前
称心的菲鹰完成签到,获得积分10
51秒前
碧蓝问安发布了新的文献求助10
52秒前
52秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136